NRAS and cancer: Unfortunately, FTIs resulted ineffective as anti-cancer drugs in advanced phase III clinical trials, as H-RAS, N-RAS and K-RAS were shown to be refractory to inactivation by FTIs and can still associate with membranes as well as continue to function [20].